Jubilant Pharmova Q3 Results
- BSE: 530019
- NSE: JUBLPHARMA
- ISIN: INE700A01033
- Sector: Biotechnology & Drugs
BSE
1,010.75
29.50 (3.01%)
29.50 (3.01%)Volume12.18 K
Updated: Fri 8 May, 2026 | 15:29:45
NSE
1,008.2027.05 (2.76%)
27.05 (2.76%)Volume1.40 L
Updated: Fri 8 May, 2026 | 15:31:39
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹2,122.50 Cr.(16.51%)
- Operating Profit₹129.10 Cr.(-27.14%)
- Profit After Tax₹55.90 Cr.(-44.60%)
- Operating Margin6.08%(-37.47%)
Note: Comparison is on YoY basis
Quarterly - Jubilant Pharmova Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,993.40 | 1,568.50 | 14.85% | 1,553.70 | 21.22% |
| Depreciation/ Amortization | 120.70 | 91.40 | 15.17% | 94.60 | 32.20% |
| Operating Income | 129.10 | 183.80 | -44.06% | 123.40 | -27.14% |
| Net Income | 55.90 | 102.80 | -53.53% | 66.80 | -44.60% |
| Other Operating Expenses Total | 410.30 | 343.80 | 4.59% | 341.70 | 2.63% |
| Net Income Before Taxes | 93.40 | 144.40 | -50.92% | 101.00 | -28.43% |
| Total Revenue | 2,122.50 | 1,752.30 | 7.94% | 1,677.10 | 16.51% |
| Selling/ General/ Admin Expenses Total | 706.40 | 564.30 | 11.03% | 581.50 | 26.12% |
| Diluted Normalized EPS | 5.01 | 7.09 | -35.72% | 4.20 | -31.13% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.